QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their ...

 hc-wainwright--co-reiterates-buy-on-biomx-maintains-15-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates BiomX (AMEX:PHGE) with a Buy and maintains $15 price target.

 biomx-says-fda-places-clinical-hold-on-phase-2b-trial-of-bx004-for-treatment-of-patients-with-cystic-fibrosis

U.S. FDA has placed a clinical hold on the Phase 2b study as it reviews data submitted by BiomX on third-party nebulizer used t...

 biomx-q2-eps-019-beats-033-estimate-cash-cash-equivalents-and-restricted-cash-of-152m-are-sufficient-to-fund-its-operations-into-q1-of-2026

Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patient...

Core News & Articles

https://www.sec.gov/Archives/edgar/data/1739174/000089542125000454/xslSCHEDULE_13G_X01/primary_doc.xml

 biomx-published-article-titled-phage-therapy-with-nebulized-cocktail-bx004-a-for-chronic-pseudomonas-aeruginosa-infections-in-cystic-fibrosis-a-randomized-first-in-human-trial-in-nature-communications

Premier research journal article provides validation for BiomX's phage therapy platform, showcasing first-in-human Phase 1b...

 wall-street-sees-3000-upside-as-this-13m-biotech-tackles-medicines-superbug-crisis-phge--the-finance-herald

https://thefinanceherald.com/wall-street-sees-3000-upside-as-this-13m-biotech-tackles-medicines-superbug-crisis-phge/

 hc-wainwright--co-maintains-buy-on-biomx-lowers-price-target-to-15

HC Wainwright & Co. analyst Joseph Pantginis maintains BiomX (AMEX:PHGE) with a Buy and lowers the price target from $21...

 biomx-q1-eps-033-beats-042-estimate

BiomX (AMEX:PHGE) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.42) by 21.43 ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION